The primary objective of the study is to evaluate at Day 1 Cycle 2, the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in patients with Multiple Myeloma.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Evaluate the detection sensitivity of the urine monoclonal component on spot urine sample
Timeframe: at the first Day of Cycle n°2 (each cycle is 28 days or 21 days)